HomeScientific Advisory Board

Scientific Advisory Board

https://stuarttherapeutics.com/wp-content/uploads/David-Board-LR.jpg

David Calkins, PhD.

Go to full bio >

https://stuarttherapeutics.com/wp-content/uploads/New-Advisory-Board-New-Ronald-LR2.png

Ronald T. Raines, PhD.

Go to full bio >

Jay Pepose

Jay Pepose , MD.

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/Vance-Headshop-LR3.png

Vance Thompson, MD.

Go to full bio >
Felipe Headshot

Felipe Medeiros

Go to full bio >

https://stuarttherapeutics.com/wp-content/uploads/Peter-LR2.png

Peter Kaiser, MD.

Go to full bio >
Rowen

Sheri Rowen, MD

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/Charles-Advisor-LR.png

Charles Wykoff, MD PhD

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/Paul-advisor-LR.png

Paul Karpecki, OD

Go to full bio >
https://stuarttherapeutics.com/wp-content/uploads/Mark-advisor.png

Mark Pennisi, MD, PhD

Go to full bio >
Lukas Scheibler

Lukas Scheibler, PhD.

Go to full bio >
POLYCOL

Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.